Publications by authors named "Marie Mykloey Haslund"
Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.
Eur J Cancer
November 2024
Introduction: Immune checkpoint inhibitors (ICIs) carry the risk of immune-related adverse events (irAEs), a significant concern as therapy has transitioned to the adjuvant setting. Balancing therapeutic benefits against potential risks is crucial, necessitating real-world data from an unselected patient population in addition to clinical trial data to ensure optimal clinical decision-making.
Methods: This nationwide real-world study assessed irAEs in patients receiving adjuvant anti-PD1 therapy, primarily nivolumab, for resected stage III-IV melanoma between 2018-2022.
Article Synopsis
- Clinical trials indicate that adjuvant immunotherapy is effective for patients with resected melanoma, and real-life data can enhance treatment decisions and patient management.
- A study analyzing the Danish Metastatic Melanoma Database found that out of 785 patients treated with anti-PD-1, a significant portion experienced strong survival rates, but many did not complete their planned therapy.
- The findings suggest that survival outcomes for real-world melanoma patients receiving anti-PD-1 are consistent with trial results, and combining ipilimumab with nivolumab does not improve patient outcomes compared to using ipilimumab alone after anti-PD-1 treatment.
Article Synopsis
- Metastatic melanoma (MM) is typically treated with a combination of nivolumab and ipilimumab, regardless of the tumor's PD-L1 expression status.
- A study in Denmark involving 1,341 MM patients revealed that 43% had high PD-L1 expression (≥1%), which was linked to better survival rates overall.
- While combination therapy showed no significant survival benefits for patients with high PD-L1, it did improve progression-free survival for those with low PD-L1 expression (<1%).
Measles, mumps and rubella (MMR) are contagious infectious diseases that can be prevented by immunization. However, MMR infections can occur in previously immunized individuals. The vaccine response is, among other factors, influenced by the combined effects of many genes.
View Article and Find Full Text PDFComparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.
Cancers (Basel)
November 2021
Article Synopsis
- Immune-related adverse events (irAEs) are common with ipilimumab and nivolumab treatment, leading to 30-40% of patients discontinuing therapy.
- A study using real-world data from the DAMMED database analyzed progression-free survival (PFS) and overall survival (OS) in patients who discontinued due to irAEs versus those who completed treatment.
- Results showed no significant difference in PFS between the two groups, but patients who discontinued had a longer OS, suggesting discontinuation due to irAEs may not negatively impact treatment efficacy.